ES2760002T3 - Métodos de tratamiento de la psoriasis de uñas y cuero cabelludo - Google Patents

Métodos de tratamiento de la psoriasis de uñas y cuero cabelludo Download PDF

Info

Publication number
ES2760002T3
ES2760002T3 ES15714136T ES15714136T ES2760002T3 ES 2760002 T3 ES2760002 T3 ES 2760002T3 ES 15714136 T ES15714136 T ES 15714136T ES 15714136 T ES15714136 T ES 15714136T ES 2760002 T3 ES2760002 T3 ES 2760002T3
Authority
ES
Spain
Prior art keywords
antibody
psoriasis
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15714136T
Other languages
English (en)
Spanish (es)
Inventor
Ajay Nirula
Hidemi Nakagawa
Kenji Ohtaki
Hiroki Matsudo
Paul Klekotka
Gregory Kricorian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen K A Inc
Original Assignee
Amgen K A Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen K A Inc filed Critical Amgen K A Inc
Application granted granted Critical
Publication of ES2760002T3 publication Critical patent/ES2760002T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
ES15714136T 2014-03-31 2015-03-19 Métodos de tratamiento de la psoriasis de uñas y cuero cabelludo Active ES2760002T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461972638P 2014-03-31 2014-03-31
US201462031850P 2014-07-31 2014-07-31
US201462041879P 2014-08-26 2014-08-26
PCT/US2015/021613 WO2015153144A1 (en) 2014-03-31 2015-03-19 Methods of treating nail and scalp psoriasis

Publications (1)

Publication Number Publication Date
ES2760002T3 true ES2760002T3 (es) 2020-05-12

Family

ID=52808190

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15714136T Active ES2760002T3 (es) 2014-03-31 2015-03-19 Métodos de tratamiento de la psoriasis de uñas y cuero cabelludo

Country Status (11)

Country Link
US (1) US20170174772A1 (enExample)
EP (1) EP3126392B1 (enExample)
JP (1) JP6596014B2 (enExample)
KR (2) KR20160130248A (enExample)
CN (1) CN106456751B (enExample)
AU (1) AU2015241373B2 (enExample)
CA (1) CA2944605C (enExample)
ES (1) ES2760002T3 (enExample)
MY (1) MY184189A (enExample)
SG (1) SG11201607881SA (enExample)
WO (1) WO2015153144A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
CN105534996B (zh) * 2016-02-24 2018-05-01 长沙佰顺生物科技有限公司 一种治疗银屑病的药物组合物
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
JP7033774B2 (ja) * 2017-08-25 2022-03-11 国立大学法人 東京大学 抗サイトカイン抗体療法
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
SG11202006782YA (en) * 2018-01-31 2020-08-28 Twi Pharmaceuticals Inc Topical formulations comprising tofacitinib
AU2019224354A1 (en) 2018-02-22 2020-10-08 Nippon Zoki Pharmaceutical Co., Ltd. IL-17a activity inhibitor and use thereof
AU2019282155A1 (en) * 2018-06-04 2021-01-07 Lars BRICHTA Topical compositions for stimulating hair growth
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
EP4028053A1 (en) * 2019-09-11 2022-07-20 Bausch Health Ireland Limited Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody
KR20220070244A (ko) * 2019-09-25 2022-05-30 도꾜 다이가꾸 전신성 강피증 치료용 의약 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
AU636608B2 (en) 1989-05-18 1993-05-06 Yeda Research And Development Co. Ltd. Tumor necrosis factor binding protein II, it's purification and antibodies thereto
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
WO1991003553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
AU642938B2 (en) 1989-12-13 1993-11-04 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
ES2145744T5 (es) 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993007863A1 (en) 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
ATE242322T1 (de) 1992-03-30 2003-06-15 Immunex Corp Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
ATE188610T1 (de) 1992-04-30 2000-01-15 Amgen Inc Methoden zur behandlung von interleukin- 1 und - tumor - nekrose - faktor - verursachten krankheiten
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
NZ306653A (en) 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
US7030565B2 (en) 2004-07-27 2006-04-18 Jerrell Penn Hollaway Lamp control circuit with selectable color signals
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
UA99716C2 (ru) * 2006-10-02 2012-09-25 Кирин-Амген Инк. Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
CN103154031A (zh) * 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
US9413463B2 (en) 2013-08-30 2016-08-09 Google Inc. Apparatus and method for efficient two-way optical communication where transmitter may interfere with receiver
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
CN106456751A (zh) 2017-02-22
EP3126392A1 (en) 2017-02-08
SG11201607881SA (en) 2016-10-28
MY184189A (en) 2021-03-24
JP2017511316A (ja) 2017-04-20
JP6596014B2 (ja) 2019-10-23
CA2944605C (en) 2023-10-17
KR20160130248A (ko) 2016-11-10
KR102530900B1 (ko) 2023-05-12
CN106456751B (zh) 2021-02-02
WO2015153144A1 (en) 2015-10-08
AU2015241373A1 (en) 2016-10-06
US20170174772A1 (en) 2017-06-22
EP3126392B1 (en) 2019-09-11
CA2944605A1 (en) 2015-10-08
KR20220093008A (ko) 2022-07-04
AU2015241373B2 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
ES2760002T3 (es) Métodos de tratamiento de la psoriasis de uñas y cuero cabelludo
ES2981062T3 (es) Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
ES2936387T3 (es) Formulaciones de anticuerpos anti-il13
JP6554155B2 (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
JP2025172841A (ja) Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
RU2759630C2 (ru) Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
CN118924895A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
JP2018502910A (ja) Ｉｌ−１７抗体の医薬製品および安定した液体組成物
ES2992409T3 (es) Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
KR20220158821A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
US20230167171A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
JP2022091967A (ja) 脊髄損傷及び疼痛を処置するための抗ＲＧＭａ（Ｒｅｐｕｌｓｉｖｅ Ｇｕｉｄａｎｃｅ Ｍｏｌｅｃｕｌｅ Ａ）アンタゴニスト抗体
US20230220089A1 (en) Methods for attenuating atopic march by administering an il-4/il-13 antagonist
TW202110892A (zh) 治療具有類風濕性關節炎的個體中疼痛之組成物及方法
JP2021147383A (ja) アトピー性皮膚炎及び関連障害を処置するための方法
WO2021018191A1 (zh) Il-17拮抗剂治疗自身免疫疾病的方法
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
CN117715938A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
HK40086852A (zh) 抗体制剂
ES2794449T3 (es) Formulación líquida que comprende un compuesto neutralizante del GM-CSF
TW202608479A (zh) 治療具有類風濕性關節炎的個體中疼痛之組成物及方法
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법